Filing Flows › Comparisons › DWTX vs ACUT
Dogwood Therapeutics vs Accustem Sciences: DWTX and ACUT compared
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $98K for Accustem Sciences (Q2 2026).
Where the money goes: DWTX and ACUT
Dogwood Therapeutics (DWTX) · Q3 2026
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Accustem Sciences (ACUT) · Q2 2026
Accustem Sciences, Q2 2026: revenue $98K, operating margin -256.7%, net loss $253K, operating cash flow −$249K. The chart follows the revenue to costs, profit and cash.
| Dogwood Therapeutics (DWTX) | Accustem Sciences (ACUT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $100K | $98K |
| Operating margin | n/m | -256.7% |
| Net earnings | −$4.9M | −$253K |
| Net margin | — | -256.7% |
| Operating cash flow | −$4.6M | −$249K |
Questions
Which is bigger, Dogwood Therapeutics or Accustem Sciences?
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $98K for Accustem Sciences (Q2 2026).
More: Dogwood Therapeutics earnings · how Dogwood Therapeutics makes money · Accustem Sciences earnings · how Accustem Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.